<DOC>
	<DOCNO>NCT01258127</DOCNO>
	<brief_summary>The main purpose randomize phase II trial evaluate clinical feasibility activity administer adjuvant chemotherapy pemetrexed/carboplatin compare vinorelbine/carboplatin patient completely resect non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>Pemetrexed/Carboplatin v Vinorelbine/Carboplatin Patients With Completely Resected Non-small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>Pemetrexed , multi-target folate antimetabolite , show clear activity non-small cell lung cancer ( NSCLC ) . In phase III study patient previously treat advanced NSCLC , efficacy single-agent pemetrexed , determine overall survival , similar docetaxel . ( Hanna et al , 2004 ) The combination carboplatin pemetrexed particular interest demonstrate good efficacy tolerable side effect profile . Phase I study evaluate pemetrexed plus carboplatin patient malignant pleural mesothelioma , show regimen efficacious well tolerate . ( Hughes et al , 2002 ) The combination oxaliplatin pemetrexed compare carboplatin pemetrexed first-line therapy advance NSCLC randomize phase II study . Response rate 27 33 % , respectively , statistically different . Toxicity carboplatin/pemetrexed arm low , doublet deliver easily well tolerate . Dose reduction occur 3.7 % cycle . ( Scagliotti et al , 2005 ) Therefore , seem reasonable test less toxic regimen patient NSCLC complete ( R0 ) resection tumor , reduce toxicity might improve feasibility drug delivery , compliance convenience treatment patient hence perhaps improve survival . The main purpose randomize phase II trial evaluate clinical feasibility activity administer adjuvant chemotherapy pemetrexed/carboplatin compare vinorelbine/carboplatin patient completely resect NSCLC .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Patients completely resect stage IB ( &gt; 4 cm ) , II , IIIA nonsquamous NSCLC . Patient must enrol begin therapy within 46 week date complete surgical resection . Fresh tissue must available genomics expression profiling . ECOG performance status 0 1 . No prior chemotherapy , radiation therapy , biologic/targeted therapy within last 5 year . Prior therapy low dose methotrexate similar medication allow therapy use treat nonmalignant condition . Age ≥18 year . No previous concomitant malignancy past 5 year curativelytreated carcinoma situ cervix , basal cell squamous cell carcinoma skin . No serious medical psychiatric illness . Signed informed consent . Required laboratory data within one week enrollment : ) ANC AGC ≥ 1500 per uL ; b ) Platelets ≥ 100,000 per uL ; c ) Total bilirubin ≤ 1.5 mg/dL ; ) Creatinine &lt; 2 mg/dL ; creatinine clearance ≥ 45 mL/min ; e ) SGOT/SGPT ≤ 1.5× ULN . Females childbearing potential ( surgically sterilize menarche 1 year post menopause ) must test negative pregnancy within 7 day prior time enrollment base serum pregnancy test . Both sexually active male female reproductive potential must agree use reliable method birth control , determine patient health care team , study 3 month follow last dose study drug . Treatment within last 30 day drug receive regulatory approval indication time study entry . Concurrent administration antitumor therapy . Inability comply protocol study procedure . Active infection require IV antibiotic , antifungal antiviral agent , opinion investigator would compromise patient 's ability tolerate therapy . Major surgery ( definitive lung cancer surgery ) within two week study serious concomitant systemic disorder , opinion investigator , would compromise safety patient compromise patient 's ability complete study . Myocardial infarction occur less 6 month inclusion , know uncontrolled arrhythmia , symptomatic angina pectoris , active ischemia , cardiac failure control medication . Contraindication corticosteroid . Inability unwillingness take folic acid vitamin B12 supplementation . Presence clinically significant thirdspace fluid collection ( example , ascites pleural effusion ) control drainage procedure prior study entry throughout study enrollment distribution pemetrexed fluid space fully understood . Inability discontinue administration aspirin dose &gt; 1300 mg/day long act , nonsteroidal antiinflammatory agent 2 day , day , 2 day dose pemetrexed ( 5 day prior longacting agent piroxicam ) . Moderate dose ibuprofen may continue . Female patient pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Pemetrexed</keyword>
	<keyword>Vinorelbine</keyword>
	<keyword>Carboplatin</keyword>
</DOC>